Startseite › Multiples Myelom › Texas › Dallas
Klinische Studien zu Multiples Myelom in Dallas, TX
17 Studien zu Multiples Myelom suchen Teilnehmer an Standorten in und um Dallas (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Teilnehmer gesuchtPhase 3
- Research Site, Dallas
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 3
- Baylor University Medical Center, Dallas
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 3
- Baylor University Medical Center, Dallas
- UT Southwestern Medical Center, Dallas
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Teilnehmer gesuchtPhase 3
- University of Texas Southwestern Medical Center, Dallas
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 2
- UT Southwestern Medical Center, Dallas
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Teilnehmer gesuchtPhase 1/2
- University of Texas - Southwestern Medical Center /ID# 271914, Dallas
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Teilnehmer gesuchtPhase 3
- Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
- Baylor University Medical Center, Dallas
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Teilnehmer gesuchtPhase 1/2
- Research Site, Dallas
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Teilnehmer gesuchtPhase 3
- Research Site, Dallas
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Teilnehmer gesuchtPhase 1
- Baylor University Medical Center, Dallas
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Teilnehmer gesuchtPhase 1/2
- University of Texas - Southwestern Medical Center /ID# 274360, Dallas
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Teilnehmer gesuchtPhase 1
- University of Texas Southwestern, Dallas
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Teilnehmer gesuchtPhase 2
- University of Texas Southwestern, Dallas
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Teilnehmer gesuchtBeobachtungsstudie
- Ut Southwestern, Dallas
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Teilnehmer gesuchtPhase 1
- University of Texas Southwestern Medical Center, Dallas
Multiples Myelom-Studien in anderen Städten
- New York City, NY60 Studien
- Boston, MA42 Studien
- Atlanta, GA41 Studien
- Houston, TX38 Studien
- Durham, NC37 Studien
- Nashville, TN32 Studien
- Denver, CO27 Studien
- Rochester, MN24 Studien
- St. Louis, MO24 Studien
- Columbus, OH24 Studien
- Baldwin Park, CA23 Studien
- Chicago, IL22 Studien
Weitere Studien in Dallas
- Brustkrebs55 Studien
- Nichtkleinzelliges Lungenkarzinom52 Studien
- Metastasierender Krebs42 Studien
- Herzinsuffizienz42 Studien
- Krebs (alle Arten)37 Studien
- Prostatakrebs36 Studien
- Kolorektales Karzinom33 Studien
- Adipositas30 Studien
- Eierstockkrebs28 Studien
- Blasenkrebs27 Studien
- Lungenkrebs27 Studien
- Endometriumkarzinom24 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.